ArticleScientific reports2025
Evaluation of myocardial fibrosis and cardiac function in fibrotic lung diseases: a prospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research sought to elucidate the possible fibrotic effects of lung diseases accompanied by fibrosis on the heart with mapping methods. In this prospective study, 35 patients with fibrotic lung disease and 17 healthy volunteer participants with no known disease were enrolled. Myocardial T1 relaxation value, lung parenchymal T1 relaxation value, diastolic dysfunction measurements were performed in the patient and control groups with a 1.5 T MR device. ECV value was calculated only in the patient group due to ethical concerns. In patients with fibrotic lung disease, myocardial native T1 relaxation value was statistically significantly higher in the patient group compared to the control group (p < 0.001). Myocardial ECV value was found to be higher in patients with fibrotic lung disease compared to literature data. In the patient group, the native T1 relaxation value of the lung parenchyma in the area thought to be morphologically fibrotic was statistically significantly higher than the native T1 relaxation value of the lung parenchyma in the control group (p < 0.001). The native T1 relaxation value of the morphologically normal lung parenchyma in the patient group was significantly higher than the lung native T1 relaxation value of the control group (p < 0.001). High myocardial native T1 relaxation values and ECV in the patient group suggest that fibrotic lung diseases, like other systemic diseases affecting the heart, may also affect the myocardium. The development of cardiac MRI techniques will facilitate the effect of fibrotic lung diseases on myocardial fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.